Drug intelligence / Profile preview

SAUG-1

Development stage: Preclinical
Lead developer: Portage Biotech
Modality: Nanoparticles → Drug Delivery Systems

Overview

**SAUG-1** is a preclinical Portage Biotech oncology candidate within the PORT-4 nanolipogel co-formulation platform for solid tumors. It is designed to co-deliver a PD-1 checkpoint inhibitor and a VEGF-targeting small-molecule tyrosine kinase inhibitor in a single nanolipogel medicine, with the objective of combining immune-checkpoint blockade and antiangiogenic activity while improving localized tumor-microenvironment delivery and limiting systemic exposure. The specific active PD-1 inhibitor and VEGF tyrosine kinase inhibitor used in SAUG-1 have not been publicly identified. ([portagebiotech.com](https://www.portagebiotech.com/our-portfolio/port-4-nanolipogel-formulations/))

Other names: SAUG 1SAUG1SAUG-1

Targets

PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on SAUG-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAUG-1.

Explore the full profile